Biomea Fusion, Inc. - 10-Q Filing
Biomea Fusion filed its Q1 2026 Form 10-Q on May 7, 2026, reporting financial results for the quarter ended March 31, 2026. The filing includes unaudited condensed balance sheets and statements of operations but does not disclose specific revenue or EPS figures. It outlines ongoing research in metabolic diseases like diabetes and obesity through clinical trials such as Covalent-101, -102, -103, GLP-1 31, and others.
Tickers: $BMEA